**Etoposide**

**Section:** 8. Immunomodulators and antineoplastics  >  8.2. Antineoplastics and supportive medicines  >  8.2.1. Cytotoxic medicines

---

**Indication**

- Germ cell tumour of testis

**INN**

- Etoposide

**Medicine type**

- Chemical agent

**List type**

- Complementary (EML) (EMLc)

**Formulations**

- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate).
- Oral > Solid: 100 mg capsule; 50 mg capsule

**EML status history**

- First added in 2015 (TRS 994)
- Changed in 2019 (TRS 1021)
- Changed in 2023 (TRS 1049)

**Sex**

- All

**Age**

- Also recommended for children

**Therapeutic alternatives**

- The recommendation is for this specific medicine

**Patent information**

- Patents have expired in most jurisdictions
- Read more about patents.

**Tags**

- Cancer

**Wikipedia**

- Etoposide

**DrugBank**

- Etoposide

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of etoposide (Powder for injection: 100 mg (as phosphate) in vial) to the EML and EMLc.

---

**Essential medicine status**

- ✔

**ATC codes**

- L01CB01

**EMLc**

- ✔

---

**Read more about patents.**

---